Citryll announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance. CIT-013 is being developed for autoimmune and chronic inflammatory diseases and other indications where NETs play an important role in pathogenesis.<\/p>\n\n\n\n
The first-in-human study is a randomised, double blind, placebo controlled, single ascending dose (SAD) study carried out by the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, a CRO specialized in early-stage human clinical trials.<\/p>\n\n\n\n
\u201cWe are very pleased with the progress made with our lead asset. This significant clinical milestone, recent preclinical studies in new indications, as well as partnering with the renowned CHDR for Citryll\u2019s first in human studies all establish a platform for future success,\u201d said Helmuth van Es, CEO of Citryll. \u201cCIT-013 has the potential to impact many diseases where NET biology is contributing to pathology, such as lupus, rheumatoid arthritis, vasculitis, sepsis, a range of serious lung inflammatory conditions and the list is growing. The next phase of development is already in full preparation, including expanding to other countries for patient studies.\u201d<\/p>\n\n\n\n